For research and educational use. PepCaddie does not sell peptides and recommends no doses.
PepCaddie
Build
Plain reference

KLOW Blend guide

PepCaddiePublished

PepCaddie provides educational summaries of published and registered research. It does not sell peptides, provide medical advice, or recommend the use of any investigational substance. Discuss health decisions with a qualified healthcare professional.

KLOW Blend is the three peptides in Glow Blend — BPC-157, TB-500 and GHK-Cu — plus a fourth, KPV. The useful question is not whether four peptides are better than three. It is what the fourth one brings, and the answer is that KPV has never been given to a human in any published study16.

The short answer

  • Studies of this four-peptide combination: none34.
  • What KPV adds in evidence: nothing measurable. No human study, no pharmacokinetics, no toxicology in any species1.
  • KPV was nominated to regulators as a cream, and barely crossed skin in laboratory testing15.
  • Attribution: with four active ingredients and no combination study, nothing a user notices can be traced to any one of them46.
  • Regulatory status: all four sit on the same FDA withdrawn-nomination list27.

What the fourth component actually brings

KPV is a three-amino-acid fragment from the tail of a natural hormone. In 2026 FDA reviewed it after a pharmacy nominated it for compounding, and searched the published literature, the trial registry, its adverse-event databases and its own records. It found no study of KPV given to a human by any route. No pharmacokinetic data. No acute toxicity study, no repeat-dose study, no genetic toxicity study, no reproductive study and no cancer study — not in people, and not in animals either1.

There is animal work, and it is reasonably consistent: KPV reduces inflammation in mice. But the best mechanistic study of it ends in an open question. KPV worked in mice, failed in the cell assay where related compounds succeeded, and did not trigger the signal those compounds use, leading its authors to conclude KPV probably does not act through the receptors it is usually associated with16. Nobody knows what it does act on.

One more thing worth knowing for a product sold for skin: KPV was nominated to FDA as a 0.1 per cent topical cream, and in laboratory testing it did not cross human skin at detectable levels without the skin first being physically perforated15.

The arithmetic problem with four ingredients

This is the difference between KLOW and its three-component sibling, and it is worth stating plainly.

Every regulatory review of these substances examined one substance at a time4. Each found the same kinds of gaps: not well characterised chemically, impurity and aggregate data missing, endotoxin data missing. Those are not abstract concerns — FDA's stated worry is an immune reaction caused by peptides clumping together or by what sits alongside them in the vial2.

Put four such substances in one solution and every one of those questions is asked four times over, plus a new set nobody has asked at all: whether they remain stable together, whether they interfere with one another, and what happens to them after injection as a mixture[unverified]. No study answers any of it.

And there is a quieter consequence for the reader. With four active ingredients and no combination study, anything a person experiences — good or bad — cannot be attributed to any single component46. That cuts both ways: it means a benefit cannot be credited to KPV, and it means a reaction cannot be blamed on one thing either.

What happened when two of them were tested together

It has been done once, in rats. Repaired Achilles tendons treated with BPC-157 alone, TB-500 alone, both, or nothing. TB-500 alone was the only arm to reach significance on tendon strength, and the authors reported directly that combining the two conferred no additional benefit over either alone3.

Their proposed explanation generalises uncomfortably for any blend: the peptides may converge on the same downstream pathway, so stacking them adds nothing. That is a hypothesis rather than a finding, from eight rats per group over four weeks, and its authors call the study exploratory. It remains the only relevant data that exists.

Status, and sport

All four components sit on FDA's list of substances nominated for compounding and then withdrawn. None is permitted27. A 2026 clinical review of this market names contamination, manufacturing impurities and inaccurate dosing among the risks it considers relevant to clinicians7.

For anyone drug tested: BPC-157 and TB-500 are both named on the 2026 prohibited list and banned at all times. GHK-Cu and KPV are not named anywhere on it — and no melanocortin term appears at all — but the list is written with catch-all wording and tells readers to check with their anti-doping organisation rather than assume8.

Read the components instead

Everything genuinely known about this product is known about its four parts, each with its own sourced page.

Where the rest of the detail lives

The interactive library on the homepage carries the fuller reference entry for KLOW Blend, including the amounts and handling notes it holds for every compound. That is general reference information, the same for every visitor.

Open the full KLOW Blend reference in the library

References

These are the sources behind this page, listed so you can read them yourself rather than take our word for it. Animal and laboratory findings do not establish that something works or is safe in people. Doses and protocols shown on a study card are that study's research parameters, not recommendations. PepCaddie does not sell peptides and does not choose a dose for anyone; this is educational material and it does not replace a qualified healthcare professional.

  • The only test of any two of these together

    2026

    Animal studyNot human evidence

    RatsBPC-157 10 µg/kg/day and TB-500 60 µg/kg/day studied4 weeksTendon strength and structure

    The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.

    Two of these four peptides have been tested together, once, in rats with repaired Achilles tendons. TB-500 alone was the only arm to reach significance on tendon strength. The authors state directly that combined treatment did not confer additional benefits compared to either agent alone, and suggest the two may simply act on the same downstream pathway.

    Limitation: Eight rats per group over four weeks, called exploratory by its own authors, and it tests two components rather than four. A single result about one pair cannot predict what four peptides do together.

    Four-arm controlled animal study: control, each peptide alone, and both combinedView study: The only test of any two of these together

  • KPV was studied for skin, and barely crossed it

    2017

    Laboratory or in-vitro studyNot human evidence

    Human skin samples in diffusion cellsSkin permeation

    Left to diffuse on its own, KPV did not cross human skin at levels the instruments could detect. It permeated only once the skin was physically perforated with microneedles, and more with an electrical current. This matters for a blend sold for skin, and it is the reason FDA questioned KPV’s usefulness as a topical agent.

    Limitation: Donated skin in a laboratory rig, with no living metabolism and no blood flow. It measures passage through a membrane rather than delivery to a target, and shows no biological effect either way.

    Laboratory permeation study comparing passive and assisted deliveryView study: KPV was studied for skin, and barely crossed it

  • What KPV appears to do, in mice

    2003

    Animal studyNot human evidence

    MiceInflammatory cell recruitment

    KPV reduced inflammatory cell accumulation in mice, but failed in the cell assay where related compounds worked, and did not trigger the signal those compounds use. The authors concluded KPV is unlikely to act through the receptors it is usually associated with. This is the best mechanistic account of KPV that exists, and it ends in an open question.

    Limitation: Acute chemical peritonitis in mice measured over hours. KPV’s effect is left unexplained even in the authors’ own hands, which makes predicting how it interacts with three other peptides impossible.

    Two induced peritonitis models plus cell-culture assaysView study: What KPV appears to do, in mice

Keep reading